Match Document Document Title
7504104 Human CDR-grafted antibody and antibody fragment thereof  
A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood...
7504101 Methods for enhancing antigen-specific immune response using antibodies that bind OX-40  
Compositions and methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells are disclosed, comprising administering to the mammal a...
7501119 Methods and molecules for modulating an immune response  
A molecule capable of potentiating immune responses and modifying existing states of immune responsiveness is described. Also described are compositions containing the molecule, as well as methods...
7501498 Alpha-fetoprotein Immu31 antibodies and fusion proteins  
The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as...
7501247 Method of treating skin inflammation  
Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17 and/or IL-23.
7501118 Human gene relating to respiratory diseases and obesity  
This invention relates to isolated nucleic acids comprising genes of human chromosome 20p13-p12 and the proteins encoded by these genes. Expression vectors and host cells containing such genes or...
7501494 Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection  
This invention is directed to deimmunized antibodies that are useful as immunotherapeutic drugs against Human Immunodeficiency Virus (HIV) and CD4-mediated autoimmune disorders. More specifically,...
7501124 Methods of inducing T-cell non-responsiveness with anti-gp39 24-31 antibodies  
Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which...
7501122 Treatment with anti-ErbB2 antibody combinations  
The present application describes methods for treating ErbB-expressing cancer with anti-ErbB2 antibody combinations.
7498028 Preparation of spheres for diagnostic tests  
The invention relates to surfactant-free reagent spheres useful for biological tests particularly those involving antigen/antibody reactions.
7498032 Methods for treating immune disorders or cancer with anti-CD40 antibodies  
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the...
7498030 Treatment with anti-ErbB2 antibodies and anti-hormonal compounds  
The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and anti-hormonal compounds, such as anti-estrogens.
7498035 Compounds of hydrophilic polymer-polycarboxyl oligopeptide and medicines, medical composite comprising above compound and use of above compound in medicines  
The present invention relates to a conjugate of hydrophilic polymer-multicarboxyl oligopeptide and drug molecule of the following formula: wherein: P is a hydrophilic polymer; m is an integer...
7498304 Angiogenesis-modulating compositions and uses  
Hedgehog agonists and antagonists can be used to regulate angiogenesis, and to prevent angiogenesis driven pathologies. Furthermore, hedgehog agonists and antagonists have utility in modulating...
7494653 Method and compositions for immunization with the Pseudomonas V antigen  
A method of inhibiting, moderating or diagnosing Pseudomonas aeruginosa infection is disclosed. In one embodiment, this method comprises inoculating a patient with an effective amount of PcrV...
7494646 Antibodies and molecules derived therefrom that bind to STEAP-1 proteins  
Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is...
7494655 Immunizing composition and method for inducing an immune response against the β-secretase cleavage site of amyloid precursor protein  
The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AβPP...
7495083 PRO940 antibodies  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7494651 TGF-β binding antibodies  
The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are...
7491389 Modulating angiogenesis  
Hemangioblasts in adult bone marrow participate in new blood vessel formation. By modulating the differentiation of hemangioblasts into blood vessel cells, angiogenesis in a particular tissue can...
7491390 Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders  
Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunosuppressive without conjugation to a therapeutic agents, as well as...
7491516 Dual specificity antibodies and methods of making and using  
Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or...
7491393 Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies  
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
7488476 B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases  
B-cell epitope peptides of HSP 65, particularly the peptides comprising the amino acid sequence substantially as denoted by SEQ ID: Nos. 1-5 and their biologically functional homologues and...
7488806 Human antibodies to human delta like ligand 4  
An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4...
7488802 Antibodies against PD-1  
This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those...
7485302 Treatment with anti-ErbB2 antibodies and chemotherapeutic agents  
The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and chemotherapeutic agents.
7485299 Serpentine transmembrane antigens expressed in human cancers and uses thereof  
Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate...
7485298 Diagnosis and treatment of human dormancy-related sequellae  
New methods for diagnosis and treatment of human dormancy syndrome-related sequellae are provided. Human dormancy syndrome (HDS) is characterized by elevated serum ratio of rT3/fT3 compared to a...
7485297 Method of inhibition of vascular development using an antibody  
Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that...
7485296 PSCA: prostate stem cell antigen and uses thereof in pancreatic cancer  
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade...
7485616 Methods of investigating, diagnosing, and treating amyloidosis  
The present invention provides a therapeutic method for removing amyloid fibrils from a patient. The present invention also provides a transgenic animal that develops systemic AA amyloidosis within...
7485456 Modulators of TNF receptor associated factor (TRAF), their preparation and use  
A DNA sequence encoding a protein capable of binding to a tumor necrosis factor receptor-associated factor (TRAF) molecule, TRAF-binding proteins, their isoforms, analogs, fragments and derivatives...
7482434 Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof  
Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with...
7482003 Treatment for asthma with α4-specific antibodies  
The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific...
7482005 Methods of treating diseases with anti-VEGF antibodies  
The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related...
7482007 Methods of inhibiting angiogenesis to treat cancer with alphavbeta3-specific antibodies  
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
7481999 Compounds and methods for modulating OB-cadherin-mediated function  
Compositions and methods for modulating OB-cadherin-mediated functions are provided. The compositions and methods employ OB-cadherin modulating agents which generally comprise one or more of: (a) a...
7479544 Anti-PRO87299 antibodies  
The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease.
7479271 Humanized anti-ghrelin antibodies  
Humanized antibodies, or antigen-binding portions thereof, that preferentially bind acylated ghrelin with respect to unacylated ghrelin, are disclosed. These molecules have high affinity and a slow...
7476385 Methods of inhibiting IgE responses to thymus-dependent antigens with the anti-gp39 antibody MR1  
Methods of suppressing a humoral immune response to a thymus-dependent (TD) antigen are disclosed. The methods involve administering to a subject a TD antigen with an antagonist of a molecule which...
7470774 Anti-pro1477 antibodies  
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
7470772 Antibody that specifically binds to Chemerin receptor ligand precursor  
The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screening assays for the identification of candidate compounds which modulate the...
7470428 Compositions and methods related to TIM-3, a Th1-specific cell surface molecule  
The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or...
7468183 Antibody immunization therapy for treatment of atherosclerosis  
The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B...
7465446 Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease  
The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
7465445 Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM  
An antibody against AILIM (alternatively called JTT-1 antigen, JTT-2 antigen, ICOS and 8F4) was found to have a significant therapeutic effect on arthrosis, for example, rheumatoid arthritis and...
7465444 Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM  
Antibodies against AILIM (also called ICOS and 8F4) were found to significantly suppress the onset of inflammatory bowel diseases (especially Crohn's disease and colitis (ulcerative colitis and...
7465790 Therapeutic antibodies  
A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the...
7462352 Methods of treatng B-cell diseases using humanized anti-CD19 antibodies  
The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies,...